Lori Leslie, MD, and Robert Figlin, MD, discuss the latest drugs and clinical trial data on CLL treatment. Dr. Leslie shares her strategy for sequencing agents, including various BTK inhibitors and venetoclax, and how she decides on treatment in patients whose disease progresses or are refractory.

Sapna Patel, MD, Associate Professor at MD Anderson Cancer Center, and Robert Figlin, MD, Deputy Director at Cedars-Sinai Cancer, discuss the clinical implications of the DREAMseq trial, showing patients with BRAF-mutant metastatic melanoma live longer if they receive first-line ipilimumab plus nivolumab.

Rana McKay, MD, Allan Pantuck, MD, and Robert Figlin, MD, discuss the recent update to the Keynote-564 study investigating adjuvant pembrolizumab in RCC and the impact on high-, medium-, and low-risk patients.  They also talk about the Disease-Free Survival (DFS) endpoint, discussing the study with patients, and the recent NCCN guidelines update.

Daniel Petrylak, MD, Professor of Medicine at the Yale Cancer Center, and Robert Figlin, MD, of Cedars-Sinai Cancer discuss recent developments at ASCO GU in muscle-invasive bladder cancer and in particular the EV-103 clinical study while also discussing the future of MIBC treatment.

Ghassan Abou-Alfa, MD and Robert Figlin, MD, discuss the presentation of the HIMLAYA clinical study at ASCO GI ’22 and how this regimen may fit in the liver cancer treatment landscape

Frederick Locke, MD and Robert Figlin, MD discuss ZUMA-7 and when to start thinking about integrating CAR-T into B-cell lymphoma treatment algorithms, the role of BMT in these patients, and how recent data presented at ASH ’21 shows that CAR-T cell therapies can work well in relapsed/refractory B-cell lymphoma.

Lajos Pusztai, MD, and Robert Figlin, MD, discuss the practicality of neoadjuvant I-O as demonstrated in KEYNOTE-522 and the application of the Oncotype DX 21-gene signature test in the RxPONDER study, both presented at the 2021 San Antonio Breast Cancer Symposium.

Naval Daver, MD, and Robert Figlin, MD, discuss FLT3, TP53, and venetoclax combinations in the management of AML patients and what to look forward to at ASH 2021.

Kathryn Arbour, MD, joins host Robert Figlin, MD, to discuss the importance of the KRAS-targeted drug, sotorasib, in the treatment of non-small cell lung cancer.

Kathryn Arbour, MD, joins host Robert Figlin, MD, to discuss the role next-generation sequencing plays in lung cancer care, the responses seen with the KRAS-targeted drug, sotorasib, in CodeBreaK100, and what optimal use of the drug will look like down the road.

Andrew Armstrong, MD and Robert Figlin, MD discuss the ARCHES study investigating the role of enzalutamide in metastatic hormone-sensitive prostate cancer, followed by a discussion of the latest treatment trends in non-metastatic hormone-sensitive prostate cancer.